PORTLAND, Ore. – Researchers at Oregon State University have developed a technique for simultaneously treating lung cancer and a serious muscle-wasting condition that often accompanies it. The study,…

In this segment, Alexander Spira, MD, PhD, engages Natalie Vokes, MD, in a discussion on the distinct biology of EGFR-mutated non–small cell lung cancer and how it informs treatment decisions in the…

Results of a new study conclude that a pathology tool powered by artificial intelligence can predict whether a patient with extensive-stage small cell lung cancer will respond to platinum-based…

Left to right: Emanuela Taioli, MD, PhD; Raja M. Flores,MD; Claudia Henschke, PhD, MD; and David F. Yankelevitz, MD.

Mass General Brigham Cancer Institute study found that patients with advanced RET fusion-positive lung cancer showed robust and durable responses.

Investigators are currently evaluating treatment with TRI-611 among patients with ALK-positive non–small cell lung cancer in a phase 1/2 trial.

MINNEAPOLIS, March 31, 2026--Investigator-initiated at a leading cancer center will provide explore BIO 300's potential.

This cohort study examines the association between significant incidental findings on lung cancer screening in the National Lung Screening Trial and the diagnosis of an extrapulmonary cancer within 1…

Christine Lovly, MD, PhD, and Matthew Lee, MD, discuss how data help shape first-line treatment decisions in EGFR-mutated non–small cell lung cancer.

Nicolas Girard, MD, PhD, discusses updated data from the phase 2 PALOMA-2 trial (NCT05498428) that were presented at the 2026 European Lung Cancer Congress.

In this study, the researchers obtained data characterizing cells from sixty different samples of human lungs. The samples came from donors who ranged from 11 to 80 years old. The data included single-cell RNA sequencing, which identifies genes that are active in a cell at one point in time.

Abstract. Small cell lung cancer (SCLC) is characterized by early metastasis, intrinsic chemoradiation resistance and tumor recurrence. Besides the lack of potentially targetable oncogenic drivers,…

A team of researchers at VCU Massey Comprehensive Cancer Center has identified a new pathway through which mutations in the tumor suppressor p53 gene—found very frequently in human tumors—hijack DNA…

SAN ANTONIO, March 10, 2026--bioAffinity Technologies launches 2,000-patient longitudinal study for its CyPath Lung noninvasive diagnostic for lung cancer.

AbstractIntroduction. Lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC) are the two major histologic subtypes of non-small cell lung cance

A nationwide analysis of adults newly diagnosed with non-small cell lung cancer found that Medicaid expansion was associated with earlier-stage diagnosis, more timely initiation of…

BACKGROUND: Extensive-stage small cell lung cancer (ES-SCLC) is an aggressive form of lung cancer associated with poor prognosis, and treatment goals are focused on prolonging survival and symptom…

Lung tumors often grow more slowly but are more likely to spread to other organs, a pattern linked to increased activity of the protein ATF4.

A severe case of COVID-19 or influenza could increase the risk of lung cancer later on, according to new research. Scientists discovered that serious viral infections can alter immune cells in the…

This device detects and characterizes lesions on low-dose CT scans, helping patients with cancer get faster, tailored care and avoid unnecessary procedures.

Abstract. Small cell lung cancer (SCLC) is a recalcitrant thoracic malignancy known for acquired chemoresistance, early metastatic spread, and poor overall survival. Lurbinectedin, a DNA minor groove…

Please enable JavaScript to proceed.

U.S. counties located closer to operational nuclear power plants have higher rates of cancer mortality than those located farther away, according to a new Harvard Chan School study.

/PRNewswire/ -- A protein made by stressed cancer cells helps lung and pancreatic tumors evade the immune system, a new study shows. Led by researchers from...

Microplastics in the air are infiltrating human lungs, triggering oxidative stress, inflammation and cellular damage that may contribute to a range of serious respiratory diseases, a comprehensive…

The study, published in Cancer Immunology Research, focuses on regulatory T cells, immune cells that normally keep the immune system from becoming overactive.

Pranshu Mohindra, MD, outlined considerations for optimizing the use of hypofractionated radiation for patients with lung cancer.

Monthly dosing reduces treatment visits while maintaining established safety and efficacy1,2 Builds on RYBREVANT FASPRO™ FDA approval to deliver the simplest and fastest combination regimen for EGFR+…

Data from the phase 3 LU005 trial found no OS benefit and high immune-related toxicity with concurrent/adjuvant atezolizumab and chemoradiation in LS-SCLC.

Injury and scarring markers are seen in association with RLA on follow-up CT following recovery from COVID-19.

Cancer Gene Therapy - Therapeutic advances with KRASG12C inhibitors and combination strategies in non-small cell lung cancer brain metastases

Early data from the KYANITE-1 study support the RMAT designation for KB707 as a treatment for those with advanced or metastatic NSCLC.

The phase 2 NORTHSTAR trial has demonstrated an EGFR-specific benefit of local consolidative therapy (LCT) in stage IV <i>EGFR</i>-mutant non–small cell lung cancer treated with osimertinib, with an…

KRAS G12D and G12C produce lung tumors with distinct microenvironmental and growth features that influence progression and survival.

About 10% to 15% of patients with ischemic stroke have a history of cancer, half of whom have active malignancy at the time of stroke. With improved cancer treatments extending patient survival, the…

The FDA is currently reviewing Summit's PD-1/VEGF bispecific as part of a chemotherapy combo for the treatment of locally advanced or metastatic non-squamous non-small cell lung cancer.

Research shows that people with advanced lung cancer can benefit from having immunochemotherapy treatment before 3pm.

Findings from the ongoing, open-label, single-group phase 2 eNRGy trial were presented in December at the 2025 North America Conference on Lung Cancer (NACLC).

Bayhealth’s mobile classroom lets students and neighbors explore Ion robotic bronchoscopy, boosting awareness, screening and career interest.

Survivors of non-small cell lung cancer are at risk for both second primary lung cancers as well as non-lung secondary malignancies years after definitive local therapy.A retrospective evaluation of…

Cell Death & Differentiation - Oncogenic p53 induces mitotic errors in lung cancer cells by recopying DNA replication forks conferring targetable proliferation advantage

Bristol Myers Squibb and Microsoft Partner to Advance AI-Driven Early Lung Cancer Detection / AI in healthcare, AI in Radiology, Artificial Intelligence in

The University of Cincinnati Cancer Center’s Tom Cunningham has received a two-year, $150,000 grant from the Lung Cancer Research Foundation (LCRF) to test approaches to neutralize an enzyme complex...

History of TB and CB were associated with increased lung cancer risk among populations with no smoking history. Future studies examining these associations should analyze more diverse populations and...

GAINESVILLE, Fla. — UF Health Cancer Institute researchers have discovered a small compound produced naturally by gut bacteria that doubled the response to…

Dr. Catherine Sears’ research seeks to change the way COPD and lung cancer are treated.